Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.62 |
| ▸ | INSR | P06213 | 9/20 | 0.62 |
| ▸ | IGF1R | P08069 | 9/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CCNK | O75909 | 3/20 | 0.47 |
| ▸ | CDK9 | P50750 | 3/20 | 0.47 |
| ▸ | CCND3 | P30281 | 2/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.47 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16656851 | 0.89 | INSR (0.60) | ALKINSRIGF1REGFRULK1 | |
| SCHEMBL15217784 | 0.88 | ALK (0.82) | ALKINSRIGF1REGFR | |
| SCHEMBL19203857 | 0.86 | ALK (0.56) | ALKINSRIGF1RPTK2CCNA2 | |
| SCHEMBL16995965 | 0.84 | ALK (0.87) | ALKINSRIGF1RLRRK2EGFR | |
| SCHEMBL11901180 | 0.81 | ALK (0.79) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL15222049 | 0.80 | ALK (0.64) | ALKINSRIGF1RPTK2 | |
| SCHEMBL15222050 | 0.78 | ALK (0.61) | ALKINSRIGF1RPTK2LRRK2 | |
| SCHEMBL11916492 | 0.78 | ALK (0.54) | ALKINSRIGF1RPTK2MAPK3 | |
| SCHEMBL11916623 | 0.78 | ALK (0.66) | ALKINSRIGF1RPTK2EGFR | |
| SCHEMBL16995962 | 0.77 | ALK (0.58) | ALKINSRIGF1RPTK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | ALK 370/4885INSR 751/4885IGF1R 477/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | ALK 265/4885INSR 985/4885IGF1R 586/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | ALK 316/4885INSR 767/4885IGF1R 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.